Therapeutic vaccines and immune-based therapies for the treatment of chronic hepatitis B: perspectives and challenges.

The treatment of chronic hepatitis B virus (HBV) infection has greatly improved over the last 10 years, but alternative treatments are still needed. Therapeutic vaccination is a promising new strategy for controlling chronic infection. However, this approach has not been as successful as initially anticipated for chronic hepatitis B. General impairment of the immune responses generated during persistent HBV infection, with exhausted T cells not responding correctly to therapeutic vaccination, is probably responsible for the poor clinical responses observed to date. Intensive research efforts are now focusing on increasing the efficacy of therapeutic vaccination without causing liver disease. Here we describe new approaches to use with therapeutic vaccination, in order to overcome the inhibitory mechanisms impairing immune responses. We also describe innovative strategies for generating functional immune responses and inducing sustained control of this persistent infection.

[1]  Ding‐Shinn Chen.  Hepatitis B vaccination: The key towards elimination and eradication of hepatitis B. , 2009, Journal of hepatology.

[2]  Y. Wen,et al.  [Advances on antigen-antibody immunogenic complex therapeutic vaccine for viral hepatitis B]. , 2009, Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology.

[3]  B. Rehermann.  Chronic infections with hepatotropic viruses: mechanisms of impairment of cellular immune responses. , 2007, Seminars in liver disease.

[4]  J. Donnelly,et al.  DNA Vaccines: Progress and Challenges1 , 2005, The Journal of Immunology.

[5]  A. Nagler,et al.  Ablation of persistent hepatitis B by bone marrow transplantation from a hepatitis B-immune donor. , 1993, Gastroenterology.

[6]  F. Chisari,et al.  Oscillating CD8(+) T cell effector functions after antigen recognition in the liver. , 2005, Immunity.

[7]  H. Ueno,et al.  Harnessing human dendritic cell subsets for medicine , 2010, Immunological reviews.

[8]  Alessandro Sette,et al.  Rational Design of a Multiepitope Vaccine Encoding T-Lymphocyte Epitopes for Treatment of Chronic Hepatitis B Virus Infections , 2007, Journal of Virology.

[9]  Melinda Fitzgerald,et al.  Immunol. Cell Biol. , 1995 .

[10]  S. Urban,et al.  T cells redirected against hepatitis B virus surface proteins eliminate infected hepatocytes. , 2008, Gastroenterology.

[11]  T. Mak,et al.  Adjuvant IL-7 antagonizes multiple cellular and molecular inhibitory networks to enhance immunotherapies , 2009, Nature Medicine.

[12]  E. Wherry,et al.  Molecular signature of CD8+ T cell exhaustion during chronic viral infection. , 2007, Immunity.

[13]  H. Davis,et al.  DNA-mediated immunization in a transgenic mouse model of the hepatitis B surface antigen chronic carrier state. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[14]  Zheng Zhang,et al.  Transfusion of autologous cytokine-induced killer cells inhibits viral replication in patients with chronic hepatitis B virus infection. , 2009, Clinical immunology.

[15]  A. Bertoletti,et al.  Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B. , 1998, The Journal of clinical investigation.

[16]  J. Kwekkeboom,et al.  Functional impairment of myeloid and plasmacytoid dendritic cells of patients with chronic hepatitis B , 2004, Hepatology.

[17]  C. Gibbs,et al.  Antiviral effect of adefovir in combination with a DNA vaccine in the duck hepatitis B virus infection model. , 2003, Journal of hepatology.

[18]  A. Prince,et al.  Successful nucleic acid based immunization of newborn chimpanzees against hepatitis B virus. , 1997, Vaccine.

[19]  A. Bertoletti,et al.  Transient restoration of anti-viral T cell responses induced by lamivudine therapy in chronic hepatitis B. , 2003, Journal of hepatology.

[20]  Adeeba Kamarulzaman,et al.  AIDS Res Hum Retroviruses , 2006 .

[21]  Z. Zou,et al.  Circulating and Liver Resident CD4+CD25+ Regulatory T Cells Actively Influence the Antiviral Immune Response and Disease Progression in Patients with Hepatitis B1 , 2006, The Journal of Immunology.

[22]  E. Rando,et al.  Phase I clinical trial in healthy adults of a nasal vaccine candidate containing recombinant hepatitis B surface and core antigens. , 2007, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[23]  A. Boonstra,et al.  Dendritic cells in chronic viral hepatitis B and C: victims or guardian angels? , 2009, Gut.

[24]  A. Bertoletti,et al.  PD‐1/PD‐L1 pathway and T‐cell exhaustion in chronic hepatitis virus infection , 2010, Journal of viral hepatitis.

[25]  P. Galle,et al.  Clinical and immunological efficacy of intradermal vaccine plus lamivudine with or without interleukin‐2 in patients with chronic hepatitis B , 2002, Journal of medical virology.

[26]  M. Maini,et al.  The molecular basis of the failed immune response in chronic HBV: therapeutic implications. , 2010, Journal of hepatology.

[27]  Y. Hiasa,et al.  In vivo immunization by vaccine therapy following virus suppression by lamivudine: a novel approach for treating patients with chronic hepatitis B. , 2005, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[28]  C. Rouzioux,et al.  Interruption of antiretroviral therapy initiated during primary HIV-1 infection: impact of a therapeutic vaccination strategy combined with interleukin (IL)-2 compared with IL-2 alone in the ANRS 095 Randomized Study. , 2007, AIDS research and human retroviruses.

[29]  S. Rahman,et al.  Combination therapy with antiviral drugs and hepatitis B vaccine in incidentally-detected and asymptomatic chronic hepatitis virus B carriers at Bangladesh. , 2010, Viral immunology.

[30]  M. Roggendorf,et al.  The woodchuck: a model for therapeutic vaccination against hepadnaviral infection. , 2010, Pathologie-biologie.

[31]  H. Senturk,et al.  Efficacy of Pre-S-containing HBV Vaccine Combined with Lamivudine in the Treatment of Chronic HBV Infection , 2009, Digestive Diseases and Sciences.

[32]  Roger Williams,et al.  Modulation of the CD8 -T-Cell Response by CD4 CD25 Regulatory T Cells in Patients with Hepatitis B Virus Infection , 2005 .

[33]  A. Untergasser,et al.  Dendritic cells take up viral antigens but do not support the early steps of hepatitis B virus infection , 2006, Hepatology.

[34]  J. Dienstag,et al.  Hepatitis B Virus Infection , 2010 .

[35]  K. Lamberth,et al.  Breaking tolerance in hepatitis B surface antigen (HBsAg) transgenic mice by vaccination with cross‐reactive, natural HBsAg variants , 2003, European journal of immunology.

[36]  Y. Sung,et al.  Correlation of antiviral T-cell responses with suppression of viral rebound in chronic hepatitis B carriers: a proof-of-concept study , 2006, Gene Therapy.

[37]  L. Nie,et al.  Autologus dendritic cell vaccine for chronic hepatitis B carriers: a pilot, open label, clinical trial in human volunteers. , 2010, Vaccine.

[38]  E. Kuipers,et al.  Regulatory T cells contribute to the impaired immune response in patients with chronic hepatitis B virus infection , 2005, Hepatology.

[39]  Lieping Chen,et al.  B7-H1 Up-Regulation on Myeloid Dendritic Cells Significantly Suppresses T Cell Immune Function in Patients with Chronic Hepatitis B1 , 2007, The Journal of Immunology.

[40]  C. Brander,et al.  Host Ethnicity and Virus Genotype Shape the Hepatitis B Virus-Specific T-Cell Repertoire , 2008, Journal of Virology.

[41]  Zheng-hong Yuan,et al.  A Randomized Controlled Phase IIb Trial of Antigen-Antibody Immunogenic Complex Therapeutic Vaccine in Chronic Hepatitis B Patients , 2008 .

[42]  A. Folgori,et al.  Prime-boost vectored malaria vaccines: Progress and prospects , 2010, Human vaccines.

[43]  F. Zoulim,et al.  Hepatitis B virus resistance to nucleos(t)ide analogues. , 2009, Gastroenterology.

[44]  M. Massari,et al.  Early kinetics of innate and adaptive immune responses during hepatitis B virus infection , 2009, Gut.

[45]  Geoffrey Dusheiko,et al.  Longitudinal Analysis of CD8+ T Cells Specific for Structural and Nonstructural Hepatitis B Virus Proteins in Patients with Chronic Hepatitis B: Implications for Immunotherapy , 2004, Journal of Virology.

[46]  M. Massari,et al.  Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B. , 2010, Gastroenterology.

[47]  A. Bertoletti,et al.  Therapeutic vaccination and novel strategies to treat chronic HBV infection , 2009, Expert review of gastroenterology & hepatology.

[48]  Mengji Lu,et al.  Immunization of Woodchucks with Plasmids Expressing Woodchuck Hepatitis Virus (WHV) Core Antigen and Surface Antigen Suppresses WHV Infection , 1999, Journal of Virology.

[49]  F. Lemonnier,et al.  Multiepitopic HLA-A*0201-Restricted Immune Response Against Hepatitis B Surface Antigen After DNA-Based Immunization , 2000, The Journal of Immunology.

[50]  C. Bréchot,et al.  Efficacy and limitations of a specific immunotherapy in chronic hepatitis B. , 2001, Journal of hepatology.

[51]  N. Horiike,et al.  Safety and efficacy of hepatitis B surface antigen-pulsed dendritic cells in human volunteers. , 2004, Hepatology research : the official journal of the Japan Society of Hepatology.

[52]  B. Tennant,et al.  Immunization with Surface Antigen Vaccine Alone and after Treatment with 1-(2-Fluoro-5-Methyl-β-l-Arabinofuranosyl)-Uracil (l-FMAU) Breaks Humoral and Cell-Mediated Immune Tolerance in Chronic Woodchuck Hepatitis Virus Infection , 2002, Journal of Virology.

[53]  P. Klenerman,et al.  Temporal analysis of early immune responses in patients with acute hepatitis B virus infection. , 2009, Gastroenterology.

[54]  D. Ganem,et al.  Hepatitis B virus infection--natural history and clinical consequences. , 2004, The New England journal of medicine.

[55]  A. Sette,et al.  Immunogenicity and Tolerogenicity of Hepatitis B Virus Structural and Nonstructural Proteins: Implications for Immunotherapy of Persistent Viral Infections , 2002, Journal of Virology.

[56]  Wei Lu,et al.  Therapeutic dendritic-cell vaccine for chronic HIV-1 infection , 2004, Nature Medicine.

[57]  G. Freeman,et al.  Restoring function in exhausted CD8 T cells during chronic viral infection , 2006, Nature.

[58]  E. Wherry,et al.  Antigen-independent memory CD8 T cells do not develop during chronic viral infection. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[59]  D. Scott‐Algara,et al.  Induction or expansion of T‐cell responses by a hepatitis B DNA vaccine administered to chronic HBV carriers , 2004, Hepatology.

[60]  G. Lau,et al.  Therapeutic vaccination of chronic hepatitis B patients with virus suppression by antiviral therapy: a randomized, controlled study of co-administration of HBsAg/AS02 candidate vaccine and lamivudine. , 2007, Vaccine.

[61]  A. Bertoletti,et al.  Protection or damage: a dual role for the virus-specific cytotoxic T lymphocyte response in hepatitis B and C infection? , 2000, Current opinion in microbiology.

[62]  A. Bertoletti,et al.  Engineering virus-specific T cells that target HBV infected hepatocytes and hepatocellular carcinoma cell lines. , 2011, Journal of hepatology.

[63]  Scott N. Mueller,et al.  Enhancing therapeutic vaccination by blocking PD-1–mediated inhibitory signals during chronic infection , 2008, The Journal of experimental medicine.

[64]  K. Eguchi,et al.  Randomized Controlled Study Investigating Viral Suppression and Serological Response following PreS 1 / PreS 2 / S Vaccine Therapy Combined with Lamivudine Treatment in HBeAg-Positive Patients with Chronic Hepatitis B , 2009 .

[65]  E. Kuipers,et al.  Intrahepatic regulatory T cells are phenotypically distinct from their peripheral counterparts in chronic HBV patients. , 2008, Clinical immunology.

[66]  B. Rehermann,et al.  Immunology of hepatitis B virus and hepatitis C virus infection , 2005, Nature Reviews Immunology.

[67]  M. Mancini-Bourgine,et al.  Hepatitis B virus as a gene delivery vector activating foreign antigenic T cell response that abrogates viral expression in mouse models , 2009, Hepatology.

[68]  W. Au,et al.  A long-term follow-up study on hepatitis B surface antigen-positive patients undergoing allogeneic hematopoietic stem cell transplantation. , 2005, Blood.

[69]  S. Pol,et al.  Therapeutic vaccination in chronic hepatitis B virus carriers , 2006, Expert review of vaccines.

[70]  N. Leung.  Treatment of chronic hepatitis B: Case selection and duration of therapy , 2002, Journal of gastroenterology and hepatology.

[71]  P. Kellam,et al.  Bim-mediated deletion of antigen-specific CD8 T cells in patients unable to control HBV infection. , 2008, The Journal of clinical investigation.

[72]  J. Trojan,et al.  Immunological monitoring during therapeutic vaccination as a prerequisite for the design of new effective therapies: induction of a vaccine-specific CD4+ T-cell proliferative response in chronic hepatitis B carriers. , 2002, Vaccine.

[73]  Y. Hiasa,et al.  Safety and immunogenicity of hepatitis B surface antigen‐pulsed dendritic cells in patients with chronic hepatitis B , 2011, Journal of viral hepatitis.

[74]  N. Petrovsky,et al.  Development of a nasal vaccine for chronic hepatitis B infection that uses the ability of hepatitis B core antigen to stimulate a strong Th1 response against hepatitis B surface antigen , 2004, Immunology and cell biology.

[75]  F. Chisari,et al.  Hydrodynamic injection of viral DNA: A mouse model of acute hepatitis B virus infection , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[76]  Roger Williams,et al.  Lamivudine plus interleukin‐12 combination therapy in chronic hepatitis B: Antiviral and immunological activity , 2005, Hepatology.

[77]  N. Horiike,et al.  Placebo-controlled trial of vaccination with hepatitis B virus surface antigen in hepatitis B virus transgenic mice. , 1997, Journal of hepatology.

[78]  P. Payette,et al.  CpG Oligodeoxynucleotides with Hepatitis B Surface Antigen (HBsAg) for Vaccination in HBsAg-Transgenic Mice , 2001, Journal of Virology.

[79]  C. Pourcel,et al.  Induction of anti‐hepatitis B surface antigen (HBsAg) antibodies in HBsAg producing transgenic mice: A possible way of circumventing “nonresponse” to HBsAg , 1993, Journal of medical virology.

[80]  J. Abastado,et al.  HBsAg/HLA-A2 transgenic mice: a model for T cell tolerance to hepatitis B surface antigen in chronic hepatitis B virus infection. , 2003, International immunology.

[81]  K. Eguchi,et al.  Randomized Controlled Study Investigating Viral Suppression and Serological Response following Pre-S1/Pre-S2/S Vaccine Therapy Combined with Lamivudine Treatment in HBeAg-Positive Patients with Chronic Hepatitis B , 2009, Antimicrobial Agents and Chemotherapy.

[82]  Se-Hwan Yang,et al.  Increase of Plasma IL-12/p40 Ratio Induced by the Combined Therapy of DNA Vaccine and Lamivudine Correlates with Sustained Viremia Control in CHB Carriers , 2009, Immune network.

[83]  D. Webster,et al.  Synergistic DNA-MVA prime-boost vaccination regimes for malaria and tuberculosis. , 2006, Vaccine.

[84]  M. Mondelli,et al.  Natural killer cells in viral hepatitis: facts and controversies , 2010, European journal of clinical investigation.

[85]  A. Bertoletti,et al.  Protection or damage: a dual role for the virus-specific cytotoxic T lymphocyte response in hepatitis B and C infection? , 2000, Current opinion in immunology.

[86]  W. M. Lee,et al.  Hepatitis B virus infection. , 1997, The New England journal of medicine.

[87]  Chung-Che Chang,et al.  Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals , 2006, Nature Medicine.

[88]  D. Scott‐Algara,et al.  Changes to the Natural Killer Cell Repertoire after Therapeutic Hepatitis B DNA Vaccination , 2010, PloS one.

[89]  C. Sunyach,et al.  Protective and therapeutic effect of DNA-based immunization against hepadnavirus large envelope protein. , 1999, Gastroenterology.

[90]  B. Engels,et al.  Redirecting T lymphocyte specificity by T cell receptor gene transfer--a new era for immunotherapy. , 2007, Molecular aspects of medicine.